470 related articles for article (PubMed ID: 25478866)
1. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
[TBL] [Abstract][Full Text] [Related]
2. Sequence, structure, and active site analyses of p38 MAP kinase: exploiting DFG-out conformation as a strategy to design new type II leads.
Badrinarayan P; Sastry GN
J Chem Inf Model; 2011 Jan; 51(1):115-29. PubMed ID: 21141877
[TBL] [Abstract][Full Text] [Related]
3. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
Badrinarayan P; Sastry GN
J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
[TBL] [Abstract][Full Text] [Related]
4. Predicting inactive conformations of protein kinases using active structures: conformational selection of type-II inhibitors.
Xu M; Yu L; Wan B; Yu L; Huang Q
PLoS One; 2011; 6(7):e22644. PubMed ID: 21818358
[TBL] [Abstract][Full Text] [Related]
5. Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.
Zhang Q; Zhang X; You Q
Molecules; 2016 Jul; 21(7):. PubMed ID: 27438814
[TBL] [Abstract][Full Text] [Related]
6. Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states.
Lake EW; Muretta JM; Thompson AR; Rasmussen DM; Majumdar A; Faber EB; Ruff EF; Thomas DD; Levinson NM
Proc Natl Acad Sci U S A; 2018 Dec; 115(51):E11894-E11903. PubMed ID: 30518564
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence labels in kinases: a high-throughput kinase binding assay for the identification of DFG-out binding ligands.
Simard JR; Rauh D
Methods Mol Biol; 2012; 800():95-117. PubMed ID: 21964785
[TBL] [Abstract][Full Text] [Related]
8. Type II Inhibitors Targeting CDK2.
Alexander LT; Möbitz H; Drueckes P; Savitsky P; Fedorov O; Elkins JM; Deane CM; Cowan-Jacob SW; Knapp S
ACS Chem Biol; 2015 Sep; 10(9):2116-25. PubMed ID: 26158339
[TBL] [Abstract][Full Text] [Related]
9. The ABC of protein kinase conformations.
Möbitz H
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1555-66. PubMed ID: 25839999
[TBL] [Abstract][Full Text] [Related]
10. Redefining the Protein Kinase Conformational Space with Machine Learning.
Ung PM; Rahman R; Schlessinger A
Cell Chem Biol; 2018 Jul; 25(7):916-924.e2. PubMed ID: 29861272
[TBL] [Abstract][Full Text] [Related]
11. Modeling conformational flexibility of kinases in inactive states.
Schwarz D; Merget B; Deane C; Fulle S
Proteins; 2019 Nov; 87(11):943-951. PubMed ID: 31168936
[TBL] [Abstract][Full Text] [Related]
12. Structure of mitogen-activated protein kinase kinase 1 in the DFG-out conformation.
Nakae S; Kitamura M; Fujiwara D; Sawa M; Shirai T; Fujii I; Tada T
Acta Crystallogr F Struct Biol Commun; 2021 Dec; 77(Pt 12):459-464. PubMed ID: 34866601
[TBL] [Abstract][Full Text] [Related]
13. Exploration and Comparison of the Geometrical and Physicochemical Properties of an αC Allosteric Pocket in the Structural Kinome.
Sturm N; Tinivella A; Rastelli G
J Chem Inf Model; 2018 May; 58(5):1094-1103. PubMed ID: 29697977
[TBL] [Abstract][Full Text] [Related]
14. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
[TBL] [Abstract][Full Text] [Related]
15. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2).
Tan L; Nomanbhoy T; Gurbani D; Patricelli M; Hunter J; Geng J; Herhaus L; Zhang J; Pauls E; Ham Y; Choi HG; Xie T; Deng X; Buhrlage SJ; Sim T; Cohen P; Sapkota G; Westover KD; Gray NS
J Med Chem; 2015 Jan; 58(1):183-96. PubMed ID: 25075558
[TBL] [Abstract][Full Text] [Related]
16. Human p38α mitogen-activated protein kinase in the Asp168-Phe169-Gly170-in (DFG-in) state can bind allosteric inhibitor Doramapimod.
Suplatov D; Kopylov K; Sharapova Y; Švedas V
J Biomol Struct Dyn; 2019 May; 37(8):2049-2060. PubMed ID: 29749295
[TBL] [Abstract][Full Text] [Related]
17. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
18. Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases.
Aleksandrov A; Simonson T
J Biol Chem; 2010 Apr; 285(18):13807-15. PubMed ID: 20200154
[TBL] [Abstract][Full Text] [Related]
19. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
Zhao H; Huang D; Caflisch A
ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
[TBL] [Abstract][Full Text] [Related]
20. Allosteric inhibition of c-Met kinase in sub-microsecond molecular dynamics simulations induced by its inhibitor, tivantinib.
Yan M; Wang H; Wang Q; Zhang Z; Zhang C
Phys Chem Chem Phys; 2016 Apr; 18(15):10367-74. PubMed ID: 27029952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
